A new study suggests that combining an antidepressant with an antipsychotic drug can significantly improve recovery rates for adults with major depression. Researchers found that adding Johnson & Johnson’s medication Caplyta (lumateperone) to standard antidepressant treatment nearly doubled the chances of remission within six weeks compared to a placebo. This six-month study, presented at the 2026 American College of Neuropsychopharmacology meeting, showed remarkable results: 65% of patients achieved remission, and 43% experienced long-lasting symptom relief. Complete remission—meaning all symptoms disappeared—occurred in 44.1% of participants, with 42.8% maintaining this improvement by the end of the 24-week study. The benefits of the combination therapy continued to grow over time, making it a promising option for lasting recovery. Dr. Michael Thase, a professor of psychiatry at the University of Pennsylvania, emphasized that these findings highlight the importance of deep and durable symptom reduction for patients and doctors seeking long-term relief. Dr. Bill Martin, a neuroscience expert at Johnson & Johnson, added that many patients struggle for years with treatments that only provide partial improvement, never realizing that complete recovery is possible. This new approach could change expectations, making remission the goal rather than just a distant hope. Caplyta was approved in the U.S. in November 2025 as an additional treatment for major depression, and it is also used for schizophrenia and bipolar disorder-related depression.